Advertisement
Canada markets close in 1 hour 24 minutes

  • S&P/TSX

    22,167.47
    -76.55 (-0.34%)
     

  • S&P 500

    5,561.65
    +24.63 (+0.44%)
     

  • DOW

    39,339.70
    +31.70 (+0.08%)
     

  • CAD/USD

    0.7335
    -0.0011 (-0.15%)
     

  • CRUDE OIL

    83.35
    -0.53 (-0.63%)
     

  • Bitcoin CAD

    77,068.95
    -2,443.07 (-3.07%)
     

  • CMC Crypto 200

    1,164.88
    -43.81 (-3.63%)
     

  • GOLD FUTURES

    2,398.80
    +29.40 (+1.24%)
     

  • RUSSELL 2000

    2,022.34
    -14.28 (-0.70%)
     

  • 10-Yr Bond

    4.2800
    -0.0750 (-1.72%)
     

  • NASDAQ

    18,335.38
    +147.08 (+0.81%)
     

  • VOLATILITY

    12.55
    +0.29 (+2.37%)
     

  • FTSE

    8,203.93
    -37.33 (-0.45%)
     

  • NIKKEI 225

    40,912.37
    -1.28 (-0.00%)
     

  • CAD/EUR

    0.6769
    -0.0023 (-0.34%)
     
MARKETS LIVE BLOG:

S&P 500 HOLDS NEAR RECORD AS U.S. JOBS DATA SHOW MORE COOLING

Stocks mostly tick upward in afternoon trading; Epic Games and Apple feud escalates

Corcept: Q1 Earnings Snapshot

Associated Press Finance
·1 min read

MENLO PARK, Calif. (AP) — MENLO PARK, Calif. (AP) — Corcept Therapeutics Inc. (CORT) on Wednesday reported first-quarter earnings of $27.5 million.

On a per-share basis, the Menlo Park, California-based company said it had net income of 25 cents.

The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for earnings of 21 cents per share.

The drug developer posted revenue of $146.8 million in the period, also topping Street forecasts. Four analysts surveyed by Zacks expected $137.8 million.

Corcept expects full-year revenue in the range of $620 million to $650 million.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on CORT at https://www.zacks.com/ap/CORT